A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours

Trial Profile

A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs LTX 315 (Primary) ; Ipilimumab; Pembrolizumab
  • Indications Advanced breast cancer; Cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Lytix Biopharma
  • Most Recent Events

    • 06 Jun 2017 Interim results (n=28) assessing effects of LTX-315 presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 Results from this trial were presented at the 2017 ASCO Meeting according to a HalioDx media release.
    • 05 Apr 2017 As of January 2017, 28 patients have been recruited as reported in trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top